8-K: Alaunos Therapeutics Secures Up to $25 Million Equity Financing Facility with Mast Hill Fund

Alaunos Therapeutics, Inc. has entered into an equity purchase agreement with Mast Hill Fund, L.P. for up to $25 million in common stock over 24 months, alongside a warrant for 79,900 shares, providing flexible access to capital.

Summary

• Alaunos Therapeutics, Inc. (the "Company") has entered into an Equity Purchase Agreement and a Registration Rights Agreement with Mast Hill Fund, L.P. (the "Investor").
• Under the Equity Purchase Agreement, Mast Hill Fund has committed to purchase up to $25.0 million of the Company's common stock over a period of up to 24 months, commencing May 19, 2025.
• The Company has the right, but not the obligation, to sell shares to Mast Hill, with Mast Hill obligated to purchase when directed, subject to certain conditions.
• Individual sales ("Puts") can range from a minimum of $5,000.00 to a maximum of the lesser of $500,000.00 or 20% of the average daily trading value (based on the 5 trading days preceding the put date) multiplied by the VWAP.
• The purchase price for these shares will be based on a discount to the VWAP or Market Price, specifically 97% (or 90% if the Principal Market is any tier of the OTC Markets).
• Concurrently, the Company issued Mast Hill Fund a warrant to purchase 79,900 shares of common stock, immediately exercisable, with an initial exercise price of $4.00 per share, expiring on May 19, 2030 (five-year anniversary of issuance date).
• The exercise price and number of shares issuable under the warrant are subject to anti-dilution adjustments for stock dividends, splits, combinations, reclassifications, and dilutive issuances. A cashless exercise option is available if the market price exceeds the exercise price.
• The aggregate number of shares issued under the Purchase Agreement and Warrant is capped at 19.99% of outstanding shares immediately prior to the execution of the Purchase Agreement (the "Exchange Cap"), unless shareholder approval is obtained.
• Mast Hill Fund's beneficial ownership is limited to 4.99% of the Company's issued and outstanding common stock.
• The Company has agreed to file a registration statement with the SEC within 60 days from May 19, 2025, and have it declared effective within 90 days, to allow for the resale of shares by Mast Hill Fund.
• The Company will reimburse Mast Hill Fund $17,500.00 for expenses incurred relating to the Purchase Agreement.

Sentiment

Score: 7

Explanation: The agreement provides Alaunos Therapeutics with a flexible and significant source of capital, which is crucial for a biotech company. While it introduces potential dilution and some restrictions, the ability to control the timing of capital raises and the anti-dilution protections for the investor are positive aspects. The terms are generally standard for this type of financing, indicating a reasonable deal for securing funding.

Positives

• Secures access to up to $25.0 million in capital over 24 months, providing financial flexibility without immediate, full dilution.
• The Company retains control over the timing and amount of stock sales, allowing it to manage capital raises based on market conditions and funding needs.
• The warrant provides additional potential capital if exercised, with an initial exercise price of $4.00.
• Anti-dilution provisions in the warrant protect the investor's economic value against future dilutive issuances by the Company.
• The agreement includes a commitment from the Company to register the shares for resale, facilitating liquidity for the investor.

Negatives

• Potential for significant future dilution for existing shareholders as shares are issued under the equity purchase agreement and warrant.
• The pricing mechanism for the "Puts" (97% or 90% of VWAP/Market Price) means shares are sold at a discount to market, which can be dilutive.
• The "Exchange Cap" of 19.99% of outstanding shares requires shareholder approval for further issuances, potentially limiting the full $25 million raise without such approval.
• The anti-dilution provisions in the warrant could lead to a lower exercise price if the Company issues shares at a lower price in the future, increasing potential dilution.
• The Company is restricted from entering into other "Equity Line of Credit" or "Variable Rate Transactions" without Mast Hill Fund's prior written consent, potentially limiting future financing options.
• The Company is responsible for Mast Hill Fund's expenses of $17,500.00.

Risks

• **Market Price Volatility**: The actual amount of capital raised will depend on the trading prices of the Common Stock, as sales are based on VWAP and subject to minimum price triggers.
• **Shareholder Dilution**: Continuous issuance of shares under the agreement and warrant will dilute existing shareholders' ownership.
• **Failure to Obtain Shareholder Approval**: If the Company fails to obtain shareholder approval for the Exchange Cap, it may not be able to draw the full $25.0 million.
• **Registration Statement Effectiveness**: The Company must maintain an effective registration statement for resale; failure to do so could impact the investor's ability to sell shares and trigger company obligations (e.g., Buy-In compensation).
• **Compliance with Listing Rules**: The Company must remain compliant with Nasdaq listing rules, including maintaining sufficient net tangible assets.
• **Litigation/Arbitration**: The agreement mandates binding arbitration for disputes, potentially limiting traditional legal recourse.
• **Beneficial Ownership Limitation**: The 4.99% beneficial ownership limit for Mast Hill could restrict the pace or size of individual "Puts."

Future Outlook

The Company intends to utilize this equity facility to access capital over the next 24 months, at its discretion, to fund operations. The effectiveness of a registration statement for the resale of shares by Mast Hill Fund is a key future step, expected within 90 days. The agreement provides a flexible financing option, but actual capital raised will depend on market conditions and the Company's strategic decisions regarding share sales.

Management Comments

• "The Company will control the timing and amount of sales of Common Stock to Mast Hill, if any."
• "Actual sales of shares of Common Stock to Mast Hill, if any, will depend on a variety of factors to be determined by the Company from time to time, including, among others, market conditions, the trading prices for the Common Stock, and determinations by the Company as to the appropriate sources of funding for the Company and its operations."
• "The Company has reviewed the Arbitration Provisions carefully, consulted with legal counsel about such provisions (or waived its right to do so), understands that the Arbitration Provisions are intended to allow for the expeditious and efficient resolution of any dispute hereunder, agrees to the terms and limitations set forth in the Arbitration Provisions, and that Company will not take a position contrary to the foregoing representations."

Industry Context

This type of equity purchase agreement, often referred to as a "standby equity purchase agreement" or "equity line of credit," is a common financing tool for smaller public companies, particularly in sectors like biotechnology, that require flexible access to capital for ongoing operations, research and development, or clinical trials. It allows companies to raise funds as needed, minimizing upfront dilution compared to a large single offering, but can lead to significant dilution over time if frequently utilized, especially at lower stock prices.

Comparison to Industry Standards

• The $25 million commitment over 24 months is a typical size and duration for an equity line of credit for a small-cap biotech company, providing a runway for operations without the immediate pressure of a large capital raise.
• The pricing mechanism (discount to VWAP) is standard for such facilities, reflecting the liquidity premium for the investor. The 97% (or 90% for OTC) discount is within the typical range for these types of agreements.
• The 19.99% Exchange Cap, requiring shareholder approval for further issuances, is a common Nasdaq listing rule compliance measure (Rule 5635(d)) to protect existing shareholders from excessive dilution without their consent.
• The 4.99% beneficial ownership limitation for the investor is also standard to avoid triggering Schedule 13D filing requirements and potential "control" implications.
• The issuance of a warrant as a commitment fee is a common component of these agreements, compensating the investor for providing the capital commitment.
• The anti-dilution provisions in the warrant are typical for protecting the investor's economic interest in case of future dilutive events by the company.

Corporate Governance

Stakeholder Impact

• **Shareholders**: Potential for significant dilution due to the issuance of new shares under the equity purchase agreement and warrant. The value of existing shares could be impacted by the discounted pricing of new shares. However, the capital infusion could support company operations and strategic initiatives, potentially benefiting long-term value.
• **Company Management**: Gains flexibility in managing capital needs over a 24-month period, allowing for opportunistic fundraising based on market conditions.
• **Mast Hill Fund, L.P. (Investor)**: Gains the right to purchase shares at a discount and a warrant, providing potential for profit. The anti-dilution provisions protect its investment.

Next Steps

• The Company must file a Current Report on Form 8-K, including the Transaction Documents as exhibits, within the time required by the Exchange Act.
• The Company must file a registration statement with the SEC within 60 days from May 19, 2025, and have it declared effective within 90 days, to register the resale of shares by Mast Hill Fund.
• The Company may, at its discretion, issue "Put Notices" to Mast Hill Fund to sell shares of common stock over the next 24 months.
• The Company must secure and maintain the listing of all issued securities on the Principal Market (Nasdaq Capital Market).
• The Company must obtain shareholder approval if it intends to issue shares exceeding the 19.99% Exchange Cap.

Key Dates

Recommendation

Keywords

Equity Purchase Agreement, Warrant, SEC Filing, Alaunos Therapeutics, Mast Hill Fund, Capital Raise, Dilution, Common Stock, Registration Rights, Anti-Dilution, Nasdaq, Biotechnology Financing, Investment Agreement, SEC 8-K